Palo Alto Immunotherapeutics

Palo Alto Immunotherapeutics (PAI) is a biotechnology company developing advanced immunotherapies for cancer treatment, specifically focusing on next-generation cancer vaccines. The company's core innovation is a proteasomal enhancing technology platform that optimizes antigen presentation by the immune system through specific amino acid substitutions, such as tyrosine. Its lead candidate, Y6-pepvIII, is a second-generation version of the rindopepimut vaccine designed to target the EGFRvIII mutation in glioblastoma. PAI is also advancing a pipeline of vaccines targeting other high-frequency mutations, including B-RAF V600E and KRAS-G12V, for various solid tumors such as colon, lung, and pancreatic cancers.